Micron Biomedical is breaking barriers to vaccine and therapeutic access with needle-free and thermostable technology that is administered quickly and painlessly via the skin to deliver medicines that otherwise require an injection using technology that has been heralded as the single-highest priority innovation to eradicate vaccine preventable diseases globally by the Vaccine Innovation Prioritisation Strategy (VIPS) alliance–a consortium between the World Health Organization, GAVI, UNICEF, PATH and the Bill & Melinda Gates Foundation. Micron’s technology allows for self-administration or administration by a caregiver or parent, reduces the need for cold chain transport and storage, can be shipped virtually anywhere and produces no medical sharps waste.
Micron has already demonstrated the safety and efficacy of its measles and rubella vaccine in Phase 1/2 trials in adults and children as young as 9 months old in sub saharan Africa, and in Phase 1 trials in influenza in the United States with additional trials being announced this year. The company is working with governmental bodies and major pharmaceutical companies to improve global accessibility and uptake of vaccines and traditionally injected treatments for a wide range of conditions including diabetes, infertility and obesity.